» Articles » PMID: 38386051

Treatment of Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage Using the Neurospeed Semi-compliant Balloon

Overview
Specialties Neurology
Radiology
Date 2024 Feb 22
PMID 38386051
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: Cerebral vasospasm (CV) following aneurysmal subarachnoid hemorrhage (aSAH) may lead to morbidity and mortality. Endovascular mechanical angioplasty may be performed if symptomatic CV is refractory to noninvasive medical management. Off-label compliant remodelling balloons tend to conform to the course of the vessel, contrary to noncompliant or semi-compliant balloons. Our objective is to describe our initial experience with the semi-compliant Neurospeed balloon (approved for intracranial stenosis) in cerebral vasospasm treatment following aSAH.

Methods: All patients included in the prospective observational SAVEBRAIN PWI (NCT05276934 on clinicaltrial.gov) study who underwent cerebral angioplasty using the Neurospeed balloon for the treatment of medically refractory and symptomatic CV after aSAH were identified. Patient demographic information, procedural details and outcomes were obtained from electronic medical records.

Results: Between February 2022 and June 2023, 8 consecutive patients underwent CV treatment with the Neurospeed balloon. Angioplasty of 48 arterial segments (supraclinoid internal carotid artery, A1 and A2 segments of the anterior cerebral artery, M1 and M2 segments of the middle cerebral artery) was attempted and 44/48 (92%) were performed. The vessel diameter significantly improved following angioplasty (+81%), while brain hypoperfusion decreased (-81% of the mean TMax). There was no long-term clinical complication, 4% periprocedural complications occurred.

Conclusion: The semi-compliant Neurospeed balloon is effective in the treatment of cerebral vasospasm following aSAH, bringing a new device into the armamentarium of the neurointerventionalist to perform intracranial angioplasty.

Citing Articles

CT perfusion imaging in aneurysmal subarachnoid hemorrhage. State of the art.

Lolli V, Guenego A, Sadeghi N, Jodaitis L, Lubicz B, Taccone F Front Radiol. 2024; 4:1445676.

PMID: 39434941 PMC: 11491345. DOI: 10.3389/fradi.2024.1445676.


Treatment of Cerebral Vasospasm after Aneurysmal Subarachnoid Hemorrhage Using the Compliant Manually Adjustable Mesh Comaneci.

Guenego A, Salim H, Wang M, Heit J, Sadeghi N, Ligot N J Belg Soc Radiol. 2024; 108(1):89.

PMID: 39431058 PMC: 11488188. DOI: 10.5334/jbsr.3714.

References
1.
Rivero-Arias O, Gray A, Wolstenholme J . Burden of disease and costs of aneurysmal subarachnoid haemorrhage (aSAH) in the United Kingdom. Cost Eff Resour Alloc. 2010; 8:6. PMC: 2874525. DOI: 10.1186/1478-7547-8-6. View

2.
Diringer M, Bleck T, Hemphill 3rd J, Menon D, Shutter L, Vespa P . Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. Neurocrit Care. 2011; 15(2):211-40. DOI: 10.1007/s12028-011-9605-9. View

3.
Loch Macdonald R . Delayed neurological deterioration after subarachnoid haemorrhage. Nat Rev Neurol. 2013; 10(1):44-58. DOI: 10.1038/nrneurol.2013.246. View

4.
Velat G, Kimball M, Mocco J, Hoh B . Vasospasm after aneurysmal subarachnoid hemorrhage: review of randomized controlled trials and meta-analyses in the literature. World Neurosurg. 2011; 76(5):446-54. DOI: 10.1016/j.wneu.2011.02.030. View

5.
Guenego A, Fahed R, Rouchaud A, Walker G, Faizy T, Sporns P . Diagnosis and endovascular management of vasospasm after aneurysmal subarachnoid hemorrhage - survey of real-life practices. J Neurointerv Surg. 2023; 16(7):677-683. DOI: 10.1136/jnis-2023-020544. View